Independent commentary by Dr David Simpson, MBChB, FRACP, FRCPA, Consultant Haematologist North Shore Hospital. His interests are in malignant haematology. He qualified and specialised in Auckland and had postgraduate training in Vancouver and Toronto. He was Assistant Professor of Bone Marrow Transplant at Rush Cancer Institute in Chicago. He has first authored a number of journal articles, reviews, abstracts, and a textbook chapter. He is active in clinical research. David is also a member of the Pharmacy and Therapeutics Committee at North Shore Hospital and the Tender Subcommittee of PHARMAC.
Myeloma NZ is a new foundation in NZ to provide a deeper level of support for those who affected by multiple myeloma. If patients or their loved one have been diagnosed with multiple myeloma, Myeloma NZ can help them learn about treatment options and point them to information and services to help them cope with the disease. www.multiplemyeloma.org.nz/ New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our CPD page.
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Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma Authors: Vogl DT et al. Summary: Forty-eight patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide and pomalidomide, and 31 who were also refractory to an anti-CD38 antibody, received oral selinexor 80mg and dexamethasone 20mg twice weekly in this phase 2 trial. The overall response rate (primary endpoint) was 21%, with no difference between the quad-refractory and penta-refractory participants (21% and 20%, respectively), and it was 35% in participants with high-risk cytogenetics (t[4;14], t[14;16] and del[17p]). The median response duration was 5 months, with 65% of responders alive at 12 months. The most common grade ≥3 adverse events were thrombocytopenia (59%), anaemia (28%), neutropenia (23%), hyponatraemia (22%), leucopenia (15%) and fatigue (15%). The adverse eventrelated dose interruption rate was 52%, the dose reduction rate was 37%, and the treatment discontinuation rate was 18%.
Comment (DS):
This was an impressively heavily pretreated population, with a median of 7 prior regimens; 48 had quad-refractory and 31 had penta-refractory myeloma. To see any response in this population is impressive. The response rate of 21% with a fixed-dose oral regimen is encouraging, especially as the toxicity was modest. With selinexor now available on a compassionate basis in NZ, we need to consider this as an option. Selinexor may find a place in early treatment regimens, although this is now becoming a crowded space. , with 11.4-month and 6.5-month longer OS durations in participants who had received 1 and ≥2 prior lines of therapy, respectively. KRd and Rd were respectively associated with adverse event-related treatment discontinuation rates of 19.9% and 21.5% and grade ≥3 adverse event rates of 87.0% and 83.3% including acute renal failure (3.8% and 3.3%), cardiac failure (4.3% and 2.1%), ischaemic heart disease (3.8% and 2.3%), hypertension (6.4% and 2.3%), haematopoietic thrombocytopenia (20.2% and 14.9%) and peripheral neuropathy (2.8% and 3.1%).
This update of the ASPIRE study shows that adding carfilzomib to lenalidomide and dexamethasone not only improves PFS, it significantly improves survival, with the median survival extended by 8 months. The patients who received this as second-line therapy had the greatest benefit, with the survival improving by nearly 1 year. In NZ, we should not feel comfortable giving patients lenalidomide and dexamethasone alone now that we know this.
Reference: J Clin Oncol 2018;36:728-34 Abstract For more information, please go to www.medsafe.govt.nz
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Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma Authors: Besse A et al.
Summary: Pharmacological targeting of ABCB1 has been shown to improve outcomes in MM, but is associated with adverse drug effects and insufficient plasma concentrations. Proteomics analysis has also revealed overexpression of ABCB1 as the most significant change in carfilzomibresistant MM cells. These researchers studied this overexpression and found that peripheral blood malignant plasma cells exhibited significant upregulation of ABCB1 compared with patients' bone marrow plasma cells.
In contrast to bortezomib, ABCB1 overexpression reduced carfilzomib's proteasome-inhibiting activity due to drug efflux, and the cytotoxicity of established drugs for treating MM was significantly reduced in ABCB1expressing MM cells. In an effort to identify potential drugs to target ABCB1, the researchers identified nelfinavir and lopinavir as potent functional modulators of ABCB1-mediated drug export. They found that these protease inhibitors were able to restore carfilzomib activity at therapeutically relevant drug concentrations, and recommended testing in clinical trials.
Comment (DS):
Myeloma patients who fail carfilzomib are usually in trouble. These preclinical data have shown that a common reason for carfilzomib resistance is increased expression of the P-glycoprotein ABCB1. In a series of experiments, removing the gene with CRISPR or inhibiting it with drugs restored carfilzomib sensitivity. The most potent drugs were the HIV antiviral drugs nelfinavir and lopinavir. Unfortunately, in NZ nelfinavir is delisted by Medsafe, but lopinavir is available. Interestingly, nelfinavir was shown to restore bortezomib sensitivity by inhibiting the unfolded protein response, although this paper shows that in contrast to carfilzomib, ABCB1 is not used for bortezomib export. The addition of inhibitors may restore carfilzomib sensitivity long enough for the next new drug to arrive.
Reference: Leukemia 2018;32:391-401 Abstract Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma Authors: Richardson PG et al. Summary: In this phase 2 trial, 92 patients who had received ≥2 prior lines of therapy, including an immunomodulatory agent, received various doses of ibrutinib with or without weekly dexamethasone 40mg in four cohorts using a Simon 2-stage design. Ibrutinib 840mg plus dexamethasone (n=43) produced the highest clinical benefit rate at 28%, with median duration of 9.2 months, and a PFS duration of 4.6 months. Grade 3-4 haematological adverse events included anaemia in 16% of participants, thrombocytopenia in 11% and neutropenia in 2%, and grade 3-4 nonhaematological adverse events included pneumonia in 7%, syncope in 3% and urinary tract infection in 3%.
Ibrutinib blocks Bruton's tyrosine kinase, a critical step in B-cell signalling, important for survival, proliferation and adhesion, so it is natural to assess its efficacy in myeloma. The best clinical benefit rate (at least a minor response) of 28% was seen with ibrutinib at 840mg and weekly dexamethasone 40mg; there was little response on monotherapy or with 560mg of ibrutinib with dexamethasone. This is a modest response. In CLL and low-grade lymphomas, drugs that target this pathway have limited effects on bone marrow disease, and similar mechanisms may be at play with myeloma. The results of this study can be seen as half full or half empty, and I am inclined to think there are better agents in development. There may be myeloma subtypes that benefit, perhaps t(11;14) myeloma, which can have a more lymphoid phenotype and was more prevalent in the cohort that received ibrutinib 840mg plus dexamethasone, but venetoclax has already established a niche for this entity. Comment (KR): This is a detailed analysis of nearly 500 patients treated in Sweden and the incidence of 6.8 per 100,000 is slightly lower than in NZ, which is currently around 8.0 per 100,000. However, the preponderance of patients over the age of 65 years is higher than in NZ, and illustrates the burden of disease in the older population. They did manage to improve on the low intervention rate of autologous transplantation that is beginning to emerge from local data. The improvement in survival is significant indicating the impact that novel agents are having on real-world studies. The capture of data from a single registry is something that NZ should endeavour to replicate.
Reference: Haematologica 2018;103:506-13 Abstract Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma Authors: Raje N et al. Summary: Adults with newly diagnosed MM (n=1718) who had ≥1 lytic bone lesion were randomised to receive subcutaneous denosumab 120mg or intravenous zoledronic acid 4mg every 4 weeks in this phase 3 trial; placebos were administered to achieve blinding, and all participants received first-line antimyeloma therapy. Denosumab was noninferior to zoledronic acid for the primary endpoint of time to first skeletal-related event (HR 0.98 [p=0.010 for noninferiority]). Notable grade 3≥ adverse events included pneumonia (the most common serious adverse event in both groups), neutropenia, thrombocytopenia and anaemia, but the rates did not very significantly between the two treatment groups, nor did the incidence of osteonecrosis of the jaw. There was one treatment-related death due to cardiac arrest in the zoledronic acid group.
Comment (KR):
This study has been in gestation for some time, as accrual was difficult and the enrolment criteria were challenging from personal experience. The rate of osteonecrosis of the jaw was similar in both groups, which was interesting. Cost will be an issue if denosumab ever gets into the clinic and will be best used in the context of renal impairment.
